Last reviewed · How we verify

Omega-3 treatment — Competitive Intelligence Brief

Omega-3 treatment (Omega-3 treatment) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Lipid-modifying agent / Anti-inflammatory. Area: Cardiovascular.

phase 3 Lipid-modifying agent / Anti-inflammatory Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Omega-3 treatment (Omega-3 treatment) — University Hospital, Toulouse. Omega-3 fatty acids reduce inflammation and modulate lipid metabolism to improve cardiovascular and metabolic outcomes.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Omega-3 treatment TARGET Omega-3 treatment University Hospital, Toulouse phase 3 Lipid-modifying agent / Anti-inflammatory

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Lipid-modifying agent / Anti-inflammatory class)

  1. University Hospital, Toulouse · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Omega-3 treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/omega-3-treatment. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: